Ticiana A. Leal, MD

Articles

Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

May 25th 2022

Before closing her discussion on advanced non–small cell lung cancer, Ticiana Leal, MD, highlights the possible role of immunotherapy in patients with concomitant KRAS/TP53 mutations.

Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18th 2022

A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.

Overcoming Barriers to Molecular Testing in NSCLC

May 18th 2022

After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.

Optimizing Use of Molecular Testing in Advanced NSCLC

May 11th 2022

Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.

Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

May 11th 2022

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

Dr. Leal on the Utilization of PD-1/PD-L1 Inhibitor Monotherapy in Lung Cancer

February 21st 2022

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC

December 2nd 2021

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

August 25th 2020

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Evidence Builds for Immunotherapy Combos in SCLC

January 10th 2018

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.